Are AnteoTech (ASX:ADO) rapid COVID tests available in Australia?

The company's rapid testing device still isn't able to be used in Australia.

| More on:
a woman inserts a swab up her nostril while conducting a rapid antigen test for COVID-19 in her home.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The AnteoTech Ltd (ASX: ADO) share price has soared since the start of the pandemic as the company has worked to create a COVID-19 rapid antigen test.

Enthusiasm surrounding the now-developed point-of-care rapid testing device has helped boost the company's stock by more than 1000% since the start of 2020.

AnteoTech's EuGeni testing device is now reportedly widely used in the United States and Europe. However, the Queensland-based company's test is facing ongoing delays for Australian approvals, much to the frustration of AnteoTech's boss.

At the time of writing, the AnteoTech share price is 31.5 cents, 3.28% higher than its previous close.

For context, the S&P/ASX 200 Index (ASX:XJO) is up 0.86% right now.

Is the AnteoTech COVID rapid test locked in TGA delays?

AnteoTech's calls for more rapid testing have been answered, but the company's product still can't be found in Australia.

AnteoTech CEO Derek Thomson reportedly told Queensland's The Courier Mail, the company pushed the state government to accept rapid tests as a measure to screen for the virus. Last week, the publication quoted Thomson as saying:

We've always said that rapid testing has a place to be used to control the pandemic and now we're seeing that play out…

There's too much stress on the PCR testing system in all Australian states and it's really not necessary to go to the full extent of doing a PCR test when you've got rapid tests readily available now.

Days after Thomson's comments, Queensland Premier Annastacia Palaszczuk declared the state would allow arriving travellers' entry after they receive a negative rapid test. Previously, arrivals had to receive a negative PCR test.

Further, Palaszczuk announced close contacts in Queensland will soon be given access to 18 million free rapid antigen tests at COVID-19 testing sites yesterday, saying:

We know the transition to RAT tests for close contacts will reduce some of the pressure we have seen at testing clinics in recent weeks, ensuring those with symptoms can be tested sooner.

Still, Thomson reportedly noted it's "quite frustrating" the Therapeutic Goods Administration hasn't approved the use of the AnteoTech's COVID-19 rapid antigen test.

That's despite the potential its approval could lead to millions more 15-minute tests being made available to Australians. The EuGeni testing device has been proven to be accurate 97.3% of the time.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »